110 related articles for article (PubMed ID: 8911006)
21. Salmonella Typhimurium strain expressing OprF-OprI protects mice against fatal infection by Pseudomonas aeruginosa.
Zhang M; Sun C; Gu J; Yan X; Wang B; Cui Z; Sun X; Tong C; Feng X; Lei L; Han W
Microbiol Immunol; 2015 Sep; 59(9):533-44. PubMed ID: 26249788
[TBL] [Abstract][Full Text] [Related]
22. Safety and immunogenicity of an oral inactivated whole-cell pseudomonas aeruginosa vaccine administered to healthy human subjects.
Cripps AW; Peek K; Dunkley M; Vento K; Marjason JK; McIntyre ME; Sizer P; Croft D; Sedlak-Weinstein L
Infect Immun; 2006 Feb; 74(2):968-74. PubMed ID: 16428742
[TBL] [Abstract][Full Text] [Related]
23. Immunization of young African green monkeys with OprF epitope 8-OprI-type A- and B-flagellin fusion proteins promotes the production of protective antibodies against nonmucoid Pseudomonas aeruginosa.
Weimer ET; Ervin SE; Wozniak DJ; Mizel SB
Vaccine; 2009 Nov; 27(48):6762-9. PubMed ID: 19744586
[TBL] [Abstract][Full Text] [Related]
24. [Obtaining of outer membrane protein I of Pseudomonas aeruginosa and assessment of its antigenic properties].
Gatypova EV; Zlygostev SA; Kaloshin AA; Mikhaĭlova NA
Zh Mikrobiol Epidemiol Immunobiol; 2008; (6):50-3. PubMed ID: 19189463
[TBL] [Abstract][Full Text] [Related]
25. Immunogenic efficacy of differently produced recombinant vaccines candidates against Pseudomonas aeruginosa infections.
von Specht BU; Gabelsberger J; Knapp B; Hundt E; Schmidt-Pilger H; Bauernsachs S; Lenz U; Domdey H
J Biotechnol; 2000 Sep; 83(1-2):3-12. PubMed ID: 11000453
[TBL] [Abstract][Full Text] [Related]
26. Safety and immunogenicity of high molecular weight polysaccharide vaccine from immunotype 1 Pseudomonas aeruginosa.
Pier GB
J Clin Invest; 1982 Feb; 69(2):303-8. PubMed ID: 6799548
[TBL] [Abstract][Full Text] [Related]
27. Systemic, nasal and oral live vaccines against Pseudomonas aeruginosa: a clinical trial of immunogenicity in lower airways of human volunteers.
Bumann D; Behre C; Behre K; Herz S; Gewecke B; Gessner JE; von Specht BU; Baumann U
Vaccine; 2010 Jan; 28(3):707-13. PubMed ID: 19887136
[TBL] [Abstract][Full Text] [Related]
28. Chimeric animal and plant viruses expressing epitopes of outer membrane protein F as a combined vaccine against Pseudomonas aeruginosa lung infection.
Gilleland HE; Gilleland LB; Staczek J; Harty RN; García-Sastre A; Palese P; Brennan FR; Hamilton WD; Bendahmane M; Beachy RN
FEMS Immunol Med Microbiol; 2000 Apr; 27(4):291-7. PubMed ID: 10727884
[TBL] [Abstract][Full Text] [Related]
29. Mannose-modified chitosan microspheres enhance OprF-OprI-mediated protection of mice against Pseudomonas aeruginosa infection via induction of mucosal immunity.
Cui Z; Han D; Sun X; Zhang M; Feng X; Sun C; Gu J; Tong C; Lei L; Han W
Appl Microbiol Biotechnol; 2015 Jan; 99(2):667-80. PubMed ID: 25381907
[TBL] [Abstract][Full Text] [Related]
30. OprF/I-vaccinated sera inhibit binding of human interferon-gamma to Pseudomonas aeruginosa.
Ding B; von Specht BU; Li Y
Vaccine; 2010 Jun; 28(25):4119-22. PubMed ID: 20433804
[TBL] [Abstract][Full Text] [Related]
31. Immunogenicity of Haemophilus influenzae type b polysaccharide-tetanus toxoid conjugate vaccine in infants.
Holmes SJ; Fritzell B; Guito KP; Esbenshade JF; Blatter MM; Reisinger KS; Keyserling HL; Rothstein EP; Bernstein HH; Feldman S
Am J Dis Child; 1993 Aug; 147(8):832-6. PubMed ID: 8352217
[TBL] [Abstract][Full Text] [Related]
32. Differences in the immunogenicity of three Haemophilus influenzae type b conjugate vaccines in infants.
Granoff DM; Anderson EL; Osterholm MT; Holmes SJ; McHugh JE; Belshe RB; Medley F; Murphy TV
J Pediatr; 1992 Aug; 121(2):187-94. PubMed ID: 1640282
[TBL] [Abstract][Full Text] [Related]
33. Clinico-immunological trials of Pseudomonas aeruginosa vaccine.
Stanislavsky ES; Balayan SS; Sergienko AI; Makarenko TA; Edvabnaya LS; Krohina MA; Rusanov VM
Vaccine; 1991 Jul; 9(7):491-4. PubMed ID: 1910233
[TBL] [Abstract][Full Text] [Related]
34. Pseudomonas aeruginosa antigens as potential vaccines.
Stanislavsky ES; Lam JS
FEMS Microbiol Rev; 1997 Nov; 21(3):243-77. PubMed ID: 9451816
[TBL] [Abstract][Full Text] [Related]
35. Safety and immunogenicity of investigational recombinant botulinum vaccine, rBV A/B, in volunteers with pre-existing botulinum toxoid immunity.
Khouri JM; Motter RN; Arnon SS
Vaccine; 2018 Apr; 36(15):2041-2048. PubMed ID: 29475762
[TBL] [Abstract][Full Text] [Related]
36. Mucosal prime-boost vaccination for tuberculosis based on TLR triggering OprI lipoprotein from Pseudomonas aeruginosa fused to mycolyl-transferase Ag85A.
Gartner T; Baeten M; Otieno S; Revets H; De Baetselier P; Huygen K
Immunol Lett; 2007 Jul; 111(1):26-35. PubMed ID: 17570535
[TBL] [Abstract][Full Text] [Related]
37. Parenteral application of a Pseudomonas aeruginosa flagella vaccine elicits specific anti-flagella antibodies in the airways of healthy individuals.
Döring G; Pfeiffer C; Weber U; Mohr-Pennert A; Dorner F
Am J Respir Crit Care Med; 1995 Apr; 151(4):983-5. PubMed ID: 7697276
[TBL] [Abstract][Full Text] [Related]
38. Enhancement of the protective efficacy of an oprF DNA vaccine against Pseudomonas aeruginosa.
Price BM; Barten Legutki J; Galloway DR; von Specht BU; Gilleland LB; Gilleland HE; Staczek J
FEMS Immunol Med Microbiol; 2002 Jun; 33(2):89-99. PubMed ID: 12052563
[TBL] [Abstract][Full Text] [Related]
39. Safety and immunogenicity of a combined hepatitis B virus-Haemophilus influenzae type B vaccine formulation in healthy adults.
Bulkow LR; McMahon BJ; Wainwright RB; Parkinson AJ; Wainwright KY; House J
Arctic Med Res; 1993 Jul; 52(3):118-26. PubMed ID: 8397580
[TBL] [Abstract][Full Text] [Related]
40. Comparison of two immunization schedules for a Pseudomonas aeruginosa outer membrane proteins vaccine in burn patients.
Kim DK; Kim JJ; Kim JH; Woo YM; Kim S; Yoon DW; Choi CS; Kim I; Park WJ; Lee N; Jung SB; Ahn BY; Nam SW; Yoon SM; Choi WJ
Vaccine; 2000 Dec; 19(9-10):1274-83. PubMed ID: 11137267
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
